GI Innovation announced on the 22nd that it has signed a memorandum of understanding (MOU) with AimedBio, a company specializing in the development of antibody-drug conjugates (ADCs), to collaborate on clinical research for treating glioblastoma (GBM). The MOU aims to obtain accelerated approval through clinical research of the combination therapy using GI Innovation's immune anticancer drug GI-102, targeting patients with recurrent glioblastoma who have undergone radiation surgery or treatment. GI-102 has already demonstrated anticancer activity in preclinical glioblastoma models. This MOU represents a collaboration led by AimedBio, founded by Professor Nam Do-hyun of Samsung Medical Center, a world-renowned authority in the field of glioblastoma, for clinical development, with future revenues from commercialization to be distributed between the two companies based on a pre-agreed ratio.
Huons announced on the 22nd that it has signed a joint sales agreement with Samjin Pharm for pharmacy-exclusive diet over-the-counter products, including Alrun tablets, Esra tablets, and Daisen capsules. These three products, under the collaboration, will be relaunched with a unified package design to help consumers recognize them as part of a single category called 'diet solutions.' Each product is designed to meet various consumer needs based on different ingredients and mechanisms of action. Esra tablets have already been co-sold with Samjin Pharm, and the introduction of Alrun tablets and Daisen capsules marks their addition as new joint sales items pursuant to the agreement.
Coreline Soft, a medical AI specialist, announced on the 22nd that it has completed the renewal of its AI-based imaging analysis software 'AVIEW' for approval from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. The renewal includes newly added functionalities for NeuroCT and LungCT, encompassing intracranial hemorrhage analysis and lung nodule analysis. NeuroCT automatically analyzes and visualizes suspected areas of intracranial hemorrhage in head and neck CT images. This provides auxiliary reading information for rapid diagnosis in emergencies and supports decision-making by doctors. LungCT conducts precise analysis of lung nodules in chest CTs, quantitatively analyzing size, shape, and changes to systematically support doctors' diagnostic decisions. It plays a crucial role in early detection and follow-up monitoring of lung cancer.
Yuhan Corporation announced the launch of its over-the-counter vitamin B drink 'Yuhan Mega Vita Liquid' on the 22nd, designed for rapid fatigue recovery and reduced physical burden. Yuhan Mega Vita Liquid is a drinkable over-the-counter medication that can quickly aid in fatigue recovery with a daily dose of one bottle. It contains taurine at the maximum daily limit of 2000 mg, according to over-the-counter standards, and incorporates active form vitamin B complex to enhance absorption and bioavailability. Additionally, it is formulated without caffeine, sugar, or fructose to minimize unnecessary stimulation. Moreover, it includes magnesium glycerophosphate and zinc gluconate to minimize gastrointestinal burden and enhance bioavailability. Magnesium glycerophosphate is easily absorbed by the body and has fewer side effects such as diarrhea, while zinc gluconate has less gastrointestinal irritation and a higher bioavailability. This mineral combination considers not only fatigue recovery but also immune maintenance and nerve stabilization effects.
SK bioscience announced on the 22nd that it has published its '2025 ESG report' on its website, consolidating ESG information from its subsidiaries, including IDT Biologika, a contract development and manufacturing organization (CDMO) acquired last year. The company incorporated systematic information about sustainability management practices and strategies over the past year, as well as performance and data by domain, into this report. Particularly, reflecting domestic and international ESG disclosure trends, it addressed significant themes according to the dual materiality assessment guidelines of the European Sustainability Reporting Standards (ESRS), distinguishing social impacts and financial perspectives. It also introduced the Impact-Risk-Opportunity (IRO) assessment, which analyzes the extent of impact that sustainability topics have on the environment, society, and corporations for the first time.
Dong-A Pharmaceutical announced on the 22nd that it will collaborate with the ice cream brand 'Before It Melts.' Before It Melts is located in Mapo-gu, Seoul, and showcases a variety of ice cream flavors made daily, establishing itself as a hotspot in Yeomni-dong. The brand has presented over 400 menu items until recently and has collaborated with various brands. To celebrate the collaboration with Before It Melts, Dong-A Pharmaceutical will run a giveaway event until August 10. Customers at Before It Melts who purchase an ice cream sorbet from Before It Melts and follow the official Instagram account of Bacchus (@dongabacchus_official) can post purchase verification on their story or feed to receive a can of Bacchus on-site.
RP Bio announced on the 22nd that it has commenced operation of its dedicated equipment for bottle packaging through a facility renovation. The activation of this facility is considered a strategy that satisfies both large-volume composition and environmental-friendly elements, compared to the previous PTP (Press Through Package) packaging method, evaluating its commercial viability and ESG (environmental, social, governance) considerations. RP Bio introduced bottle packaging equipment in collaboration with Daewoong Pharmaceutical last December and plans to continuously expand its application product range based on a stable operating system. Products that have adopted bottle packaging so far include Daewoong Pharmaceutical's Easy-En 6 Année, Easy-En 6 Pro, Easy-En 6 Eve series, and Teragen Etex's Vitamin Selvicom, among others, transitioning to bottle packaging.
Korea GSK announced on the 22nd that it successfully concluded the 'START Symposium' to celebrate the launch of its respiratory syncytial virus (RSV) vaccine 'Araxvi' from June 9 to July 21. The symposium, held in May to commemorate the domestic launch of Araxvi, took place under the theme 'START,' signifying the beginning of the domestic environment for preventing RSV infection that Araxvi will lead. This symposium occurred 12 times across 10 cities nationwide (Seoul, Pangyo, Chuncheon, Wonju, Daejeon, Gwangju, Yeosu, Jeonju, Daegu, Busan), featuring 24 leading domestic infectious disease and respiratory medicine specialists serving as chairs and speakers.
Carelabs, a digital healthcare platform company, announced on the 22nd that it has completed the acquisition of the elderly care worker matching platform 'Yobosarang' business unit from the Korea Senior Research Institute. Established in 2012, Carelabs operates medical digital marketing solutions, hospital CRM solutions, smart hospital solutions, and a medical staffing recruitment platform, along with training for nursing assistants. Additionally, together with its subsidiaries, including the non-face-to-face medical platform 'GoodDoc,' beauty medical information platform 'Babitalk,' and prescription information system company 'Edivi,' it is leading efforts to establish an ecosystem that integrates digital technology across the entire healthcare process from patients to medical staff, hospitals, and pharmacies.
Chaseng Korean Medicine Hospital announced on the 22nd that it invited a patient who received non-surgical spinal treatment in Mongolia 11 years ago to South Korea for integrated Korean medical treatment. From the 7th, the hospital conducted integrated Korean medical treatment for Narangchek (44), a Mongolian national with lumbar disc herniation, over about two weeks, utilizing acupuncture, pharmacopuncture, chuna manual therapy, and herbal prescriptions. This treatment was part of a sponsorship activity where the hospital directly invited the patient and covered medical expenses.